The European Commission is requesting input from stakeholders, including drug and device companies, as to "how the consultation with stakeholders in the Health Technology Assessment (HTA) network's activities could be facilitated."
An "informal" HTA network of member state entities that conduct relative effectiveness work-such as the UK's NICE and Germany's IQWiG-was mandated in 2011 "to support collaboration between Member States in developing and sharing methodologies for health technology assessment including relative effectiveness assessment (Article 15 of Directive 2011/4)."
The Directive also requires stakeholder participation in "the work of the network."
Read more: